Related Experiment Video
Updated: Jul 1, 2025
08:25
Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System
Published on: April 11, 2018
15.3K
Comparative Study of Eclipse and RayStation Multi-Criteria Optimization-Based Prostate Radiotherapy Treatment
John Y K Wong1,2, Vincent W S Leung1, Rico H M Hung2
1Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Diagnostics (Basel, Switzerland)
|March 13, 2024
Summary
This study found Eclipse MCO-based prostate radiotherapy plans offered superior quality compared to RayStation. Differences were observed between ideal and deliverable plans, impacting dosimetric outcomes.
Area of Science:
- Radiation Oncology
- Medical Physics
- Cancer Treatment
Background:
- Multi-criteria optimization (MCO) functions in radiotherapy planning systems aim to enhance treatment plan quality.
- Commercial systems like Eclipse and RayStation offer MCO, but direct comparisons for prostate cancer are lacking.
Purpose of the Study:
- To compare the quality of prostate radiotherapy plans generated using MCO functions in Eclipse and RayStation.
- To evaluate discrepancies between Pareto optimal and final deliverable plans.
- To assess the dosimetric impact of final deliverable plans in prostate cancer radiotherapy.
Main Methods:
- 25 prostate cancer patient CT datasets were used for planning in Eclipse (v16.1) and RayStation (v12A).
- MCO planning focused on PTV76 D98% (76 Gy prescription) and Rectum D50% as trade-off criteria.
- Plan quality was assessed by comparing Pareto optimal vs. final deliverable plans and evaluating dosimetric parameters (PTV, rectum dose, PTV HI, CI) using t-tests.
Main Results:
- Both systems exhibited discrepancies between Pareto optimal and final deliverable plans.
- Eclipse showed -0.89% (PTV D98%) and -2.49% (Rectum D50%) discrepancies; RayStation showed 3.56% (PTV D98%) and -1.96% (Rectum D50%).
- Eclipse plans demonstrated statistically superior PTV D98%, HI, CI, and lower mean rectal dose (76.07 Gy, 0.06, 1.05, 39.36 Gy) compared to RayStation (70.43 Gy, 0.11, 0.87, 51.65 Gy) (p < 0.001).
Conclusions:
- Eclipse's MCO function resulted in higher quality prostate radiotherapy plans compared to RayStation.
- Significant dosimetric differences were found between the two systems, favoring Eclipse for target coverage and organ-at-risk sparing.
Related Concept Videos
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
01:20Comparing the Survival Analysis of Two or More Groups
186
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
186